arrow
A

Ali S. Omrani

communicable diseases center
H指数:30
被引数:4,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection

铜绿假单胞菌血流感染患者的临床、微生物学和分子特征,预后及死亡风险因素

2026-08-180
OAAI
Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar

卡塔尔BNT162b2 COVID-19疫苗接种后加强针接种的纵向血浆蛋白质组学变化

2026-04-270
OAAI
Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar

卡塔尔手工艺与体力劳动者在接种COVID-19 BNT162b2-mRNA基础加强疫苗后的纵向细胞免疫和体液免疫反应

2025-03-270
OA
Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial
2024-09-061
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
The paucity of morality in everyday talk
2023-04-128
OAAI
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
2023-02-021
OAAI
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
2022-10-0413
OAAI
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
2022-05-1228
OAAI
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
2022-02-1733
OAAI